A larger retrospective single-center study from China by Wang et al of 16 recipients of liver transplant who received PD1 therapy for HCC documented ACR in 9 patients (incidence of 56%, 5 received pembrolizumab) with a median time of ACR within 1 week of LT and a median FK level at the time of ACR of 7 μg/L. Here, PDCD1 is linked to hepatocellular carcinoma.